Quarterly ResultAug 12, 2026, 04:25 PM

First Tracks Q2 Net Loss $33.4M; ANB033 Gets FDA Fast Track

AI Summary

First Tracks Biotherapeutics reported its second quarter 2026 financial results, with a net loss of $33.4 million, or $0.95 per share, an improvement from the prior year. The company ended the quarter with $168.0 million in cash, cash equivalents, and investments, extending its cash runway into Q2 2028. Key business updates include the FDA granting Fast Track designation for ANB033 in celiac disease and anticipated top-line data from its Phase 1b ANB033 trials in celiac disease (Q4 2026 and Q1 2027) and eosinophilic esophagitis (Q3 2027).

Key Highlights

Cash, cash equivalents and investments totaled $168.0 million as of June 30, 2026.
Q2 2026 R&D expenses were $25.6 million, down from $39.3 million in Q2 2025.
Q2 2026 G&A expenses were $9.3 million, up from $6.6 million in Q2 2025.
Q2 2026 net loss was $33.4 million, or $0.95 per share, compared to $42.4 million, or $1.47 per share in Q2 2025.
ANB033 received U.S. FDA Fast Track designation for celiac disease treatment.
Top-line data for ANB033 Phase 1b celiac disease Cohort 1 reaffirmed for Q4 2026.
Top-line data for ANB033 Phase 1b celiac disease Cohort 2 anticipated in Q1 2027.
Cash runway reiterated into Q2 2028, including expansion into two additional indications in H1 2027.

View SEC Filing

TRAXV

Pharmaceutical Preparations

First Tracks Biotherapeutics, Inc.

Price Impact